Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial

Article Abstract:

Changes in regional fat measured by dual-energy X-ray absorptiometry (DEXA) and circumferences over 64 weeks in HIV-infected individuals initiating their first antiretroviral regimen are examined. A mixed pattern of changes in central and peripheral fat over the first 64 weeks after initiation of antiretroviral therapy is observed and the changes were correlated positively, as were changes in waist and hip circumferences.

Complications and side effects, Medical examination, HIV infection, HIV infections, Adipose tissues, Adipose tissue

---

Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: Lessons learned

Article Abstract:

A report on the incidence of clinical and laboratory defined pancreatitis in HIV-1-infected individuals treated with antiretrovirals (ARVs) is presented. The principal findings are that the combination of nucleoside reverse transcriptase inhibitors (NRTIs) selected and the pancreatitis definition chosen seem to have an impact on the incidence of pancreatitis.

HIV patients, Dosage and administration, Pancreatitis

---

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989 - 1999)

Article Abstract:

A retrospective analysis was conducted on 16 United States AIDS Clinical Trials Group to understand predictors of severe hepatotoxicity (SH). It was seen that Hepatitis C virus coinfection was associated with an increased risk of SH.

AIDS (Disease), Hepatitis C virus, Clinical report

Similar abstracts:

• Abstracts: Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384
• Abstracts: Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients
• Abstracts: HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia
• Abstracts: Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene
• Abstracts: Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.